IN2014MN01384A - - Google Patents

Info

Publication number
IN2014MN01384A
IN2014MN01384A IN1384MUN2014A IN2014MN01384A IN 2014MN01384 A IN2014MN01384 A IN 2014MN01384A IN 1384MUN2014 A IN1384MUN2014 A IN 1384MUN2014A IN 2014MN01384 A IN2014MN01384 A IN 2014MN01384A
Authority
IN
India
Prior art keywords
amino acids
hiv
fusion
inhibitor
pharmaceutical composition
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce Albert Malcolm
Johannes Wilhelmus J Thuring
Christophe Francis Robert Nestor Buyck
Wim Bert Griet Schepens
Maria Aldegonda Jacoba Kriek
Wilhelmus Martinus Maria Schaaper
Jelle Wouter Slootstra
Peter Timmerman
Original Assignee
Janssen R & D Ireland
Pepscan Systems Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland, Pepscan Systems Bv filed Critical Janssen R & D Ireland
Publication of IN2014MN01384A publication Critical patent/IN2014MN01384A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN1384MUN2014 2011-12-19 2012-12-18 IN2014MN01384A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11194340 2011-12-19
PCT/EP2012/075956 WO2013092591A1 (fr) 2011-12-19 2012-12-18 Inhibiteurs de fusion membranaire du vih

Publications (1)

Publication Number Publication Date
IN2014MN01384A true IN2014MN01384A (fr) 2015-04-03

Family

ID=47501221

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1384MUN2014 IN2014MN01384A (fr) 2011-12-19 2012-12-18

Country Status (8)

Country Link
US (1) US20140357577A1 (fr)
EP (1) EP2794636A1 (fr)
JP (1) JP2015502378A (fr)
CN (1) CN104159914A (fr)
BR (1) BR112014014917A2 (fr)
IN (1) IN2014MN01384A (fr)
RU (1) RU2014129907A (fr)
WO (1) WO2013092591A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163567A2 (fr) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Inhibiteurs peptidomimétiques en hélice alpha inédits et leurs méthodes d'utilisation
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339069B1 (en) * 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
EP1452868A2 (fr) 2003-02-27 2004-09-01 Pepscan Systems B.V. Procédé pour sélectionner un médicament d'intérêt potentiel
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
EP1708734A4 (fr) * 2004-01-07 2009-06-17 Trimeris Inc Peptides synthetiques derives de la hr2 de la gp41 du vih, et leur utilisation dans une therapie destinee a inhiber la transmission du virus de l'immunodeficience humaine
US7863239B2 (en) * 2005-01-24 2011-01-04 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
EP1989220B1 (fr) * 2006-02-02 2011-12-14 Trimeris, Inc. Peptides inhibiteurs de fusion du vih à propriétés biologiques améliorées
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CA2644057A1 (fr) * 2006-02-28 2007-09-07 Trustees Of Boston University Procedes d'identification de facteurs associes a la croissance musculaire et leurs utilisations
JP2009529007A (ja) * 2006-02-28 2009-08-13 イーライ リリー アンド カンパニー 選択的ｖｐａｃ２受容体ペプチドアゴニスト
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound

Also Published As

Publication number Publication date
WO2013092591A1 (fr) 2013-06-27
US20140357577A1 (en) 2014-12-04
EP2794636A1 (fr) 2014-10-29
BR112014014917A2 (pt) 2018-05-15
CN104159914A (zh) 2014-11-19
JP2015502378A (ja) 2015-01-22
RU2014129907A (ru) 2016-02-10

Similar Documents

Publication Publication Date Title
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
CO6811816A2 (es) Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminiácidos no naturales
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
ECSP13012534A (es) Composición farmacéutica
WO2011036564A3 (fr) Souches de shigella à hyperblebs
PH12015501156A1 (en) Pharmaceutical compositions
EP3363458A3 (fr) Peptide
IL231421A (en) Lupane and its similar compounds are preserved in position 3ß by carboxy-alkyl-carbonyl-oxy and position 17- by (alkyl-conserved) amino, and also anti-HIV drug preparations containing them
CA2864145A1 (fr) Peptide induisant une autophagie
IN2014CN00572A (fr)
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2012047267A3 (fr) Immunogène polyvalent
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
PH12014500054A1 (en) Formulations that stabilize proteins
EA201300733A1 (ru) Рекомбинантные микобактерии в качестве вакцины
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
EP2747779A4 (fr) Vaccin contre le virus de l'herpès simplex sous forme de nanoémulsion
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
MX2014014878A (es) Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv).
WO2012115903A3 (fr) Souche de levure pour la production de protéines avec une o-glycosylation modifiée